WillItSurvive
Pharma and healthcare groups · United States

Zimmer Biomet Holdings

zimmerbiomet.com ↗

Makes hip and knee implants and robotic surgery systems like ROSA for joint replacement.

Hard to displace
Assessed 20 July 2026 · Evidence as of 20 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 20 July 2026 · Checkable from early 2027 · Every call on the record Checkpoint: Monogram autonomous knee robot commercialization target
The call

Zimmer Biomet sits inside a three-company club that FDA rules and surgeon habit protect from software-only attackers, while Stryker's robot chips away at its lead.

Zimmer Biomet sells artificial joints and surgical robots to orthopedic surgeons, competing mainly against Stryker and J&J's DePuy Synthes unit. It is very hard to replace because the FDA requires decades of safety data, surgeons stick with what they know, and Zimmer already has thousands of its ROSA robots installed in hospitals, all of which takes years to build. The company is adding AI tools like Monogram and OrthoGrid to its robots rather than being threatened by them, because software alone cannot get past FDA rules or surgeon trust. The big question is whether Stryker's Mako robot takes share from Zimmer's ROSA, and whether Zimmer's shift from contractor salespeople to full-time employees actually speeds up growth or slows it down.

Why
01
AI pressure: Stryker Mako, J&J Velys, Monogram Technologies. AI-guided robots are becoming table stakes in joint replacement; Zimmer owns Monogram and ROSA rather than facing an outside AI attacker. Could AI do the core job? Unlikely.
02
Bigger players: Stryker and J&J DePuy Synthes. Stryker's Mako robot has more installs and mindshare than ROSA in some U.S. markets, pressuring Zimmer's robotics story. Could a giant copy it? No, they are blocked.
03
What protects it. Decades of surgeon relationships, FDA clearances, and an installed base of about 2,000 ROSA robots that competitors can't just code around.
What would change this call
Stryker or J&J report Mako/Velys installed base overtaking ROSA's ~2,000 units by 2027. Would show rival robotics platforms outpacing ROSA in surgeon adoption.
Monogram's autonomous TKA commercialization slips past its early 2027 target date. Would show Zimmer's next-gen robotics falling behind Stryker and J&J timelines.
Q2 2026 earnings (Aug 5, 2026) show organic growth dropping below mid-single digits. Would show sales-force transition or rival pressure eroding underlying growth.
Key numbers
  • FY2025 revenue $8.232B, up 7.2% (2026-02-10)
  • ~2,000 ROSA robots installed worldwide (2025-10-07)
  • Market cap ~$17.6B, shares ~$90 (2026-07-20)
Named risks
  • Sales-force transformation from 1099 contractors to direct reps could create lasting revenue drag if not completed cleanly through 2026. Severity: medium
  • Stryker's Mako and J&J's Velys robots could take material share from ROSA and Monogram over 2026 to 2027. Severity: high
  • Monogram's fully autonomous knee robot commercialization, targeted for early 2027, could slip or fail to gain surgeon traction. Severity: medium
  • CFO vacancy since April 2026 with only an interim leader in place during a period of active M&A and guidance execution. Severity: medium
  • Active litigation including Embody earnout fraud claim and CPT Hip System multidistrict litigation remains unresolved as of July 2026. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Stryker Corporationlosing toStryker's Mako has taken robotics share for years versus ROSA per analyst commentary through 2026
Johnson & Johnson (DePuy Synthes)contestingCo-equal oligopolist with Velys robotics platform competing directly against ROSA and Monogram
Pixee MedicalcontestingZimmer Biomet filed a trade-secrets and non-compete lawsuit against a former VP now CEO of Pixee, July 2026
Smith and NephewcontestingNamed as defendant in a related Indiana non-compete case; permanent injunction entered November 2025
Enovis CorporationcontestingListed among joint reconstruction and orthopedic peers per GM Insights market analysis, May 2026
Questions people ask
Is Zimmer Biomet profitable in 2026?
Yes. Zimmer Biomet reported Q1 2026 net earnings of $238.1 million (adjusted $409.4 million) on $2.087 billion in revenue, up 9.3% year over year, with adjusted diluted EPS of $2.09 beating consensus of $1.86, as of April 28, 2026.
Could AI replace Zimmer Biomet's surgeons or implants?
No. AI is being absorbed as a feature Zimmer Biomet owns, not a replacement threat. Its Monogram robot (FDA-cleared March 2025) and ROSA platform (~2,000 installs worldwide as of October 2025) still require FDA clearance, surgeon training, and physical implant hardware that software alone cannot replicate.
Who is Zimmer Biomet's biggest competitor?
Stryker Corporation, particularly through its Mako robotics platform, which has been taking robotics share for years; Johnson & Johnson's DePuy Synthes is the other co-equal rival. Zimmer Biomet holds roughly 18% joint reconstruction share as of May 2026, near parity with Stryker.
Has Zimmer Biomet had layoffs recently?
No broad layoffs are reported; headcount is roughly flat to modestly growing, around 17,000 per company filings for FY2024 and FY2025 year-end, and the company announced plans in mid-2026 to hire 500 people over three years for a new India technology center.
What is Zimmer Biomet's revenue guidance for 2026?
As of the April 28, 2026 earnings release, Zimmer Biomet guided FY2026 revenue to $8.4 to $8.6 billion and adjusted EPS to $8.40 to $8.55, following FY2025 net sales of $8.232 billion, up 7.2% reported.
Who owns Zimmer Biomet?
Zimmer Biomet is an independent public company (NYSE/SIX: ZBH) with no controlling parent, headquartered in Warsaw, Indiana. It spun off from Bristol-Myers Squibb in 2001 and took its current name after merging with Biomet in 2015. Market cap was about $17.6 billion as of July 20, 2026.
Timeline
  • 2026-06-30Announced Iovera cryoneurolysis acquisition from Pacira, up to $140M, expected close Q3 2026
  • 2026-04-28Q1 2026 results: $2.087B revenue, +9.3%; CFO departure and interim CFO Paul Stellato announced
  • 2026-04-07Appointed Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer
  • 2026-02-10FY2025 results: $8.232B net sales, +7.2%; board approved $1.5B buyback authorization
  • 2025-10-07Completed Monogram Technologies acquisition, targeting fully autonomous knee robot commercialization by early 2027
  • 2025-04-21Completed Paragon 28 acquisition for approximately $1.2B enterprise value
  • 2025-03Monogram's AI-navigated robotic TKA system received FDA 510(k) clearance
  • 2024-08Acquired OrthoGrid Systems, AI surgical guidance technology for hip replacement
Revision history
20 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Vertex PharmaceuticalsTenet HealthcareIntuitive Surgical
More in Pharma and healthcare groups →
Sources